15 Small-Cap Stocks with High Potential
In this article, we will take a look at the 15 small-cap stocks with high potential. To skip our analysis of the latest trends, and market activity, you can go directly to see the 5 Small-Cap Stocks w...
- Supported exchanges /
- F /
- 7R8.F
Replimune Group Inc (7R8 F) stock market data APIs
€11.2
0.1(0.9%)
as of October 30, 2024
Price chart is built with Anychart
Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.
Replimune Group Inc Financial Data Overview
| 11.1 | |
| 11.2 | |
| - | |
| 11.2 | |
| 11.1 | |
| 4.56-13 | |
| 783 M | |
| 68 321 K | |
| 0 | |
| 1.214 |
Our easy-to-use no-coding solutions help you get the data effortlessly:
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
General: {
Code:
'7R8',
Type:
'Common Stock',
Name:
'Replimune Group Inc',
Exchange:
'F',
CurrencyCode:
'EUR',
CurrencyName:
'Euro',
CurrencySymbol:
'€',
CountryName:
'Germany',
CountryISO:
'DE',
OpenFigi:
NULL,
ISIN:
NULL,
CIK:
NULL,
EmployerIdNumber:
NULL,
FiscalYearEnd:
'March',
IPODate:
NULL,
InternationalDomestic:
NULL,
Sector:
'Healthcare',
Industry:
'Biotechnology',
CUSIP:
NULL,
}
Replimune Group Inc Fundamental Data is available in our Financial Data APIs
- Net Revenue 0
- EBITDA -231 756 992
- Earnings Per Share -3.02
- Income Statements
- Balance Sheets
- Cash flows
of Fundamental API Data
Get Replimune Group Inc Earnings via APIs
- Latest Release 2024-11-05
- EPS/Forecast NaN
Get Replimune Group Inc End-of-day Data via APIs
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Get Replimune Group Inc latest news via APIs
DISCO Pharmaceuticals launches as the surfaceome company with EUR 20 Million in Seed Financing
Transformative surfaceome discovery technology enables a comprehensive map of the cancer cell surface to identify a multitude of novel druggable targets. Pipeline programs in Small Cell Lung Cancer a...
Do you have any questions?
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
